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It is well demonstrated that bacteria have become resistant to common medications recently and it is considered to be one 
of the major threats to human health. The research on innovative antimicrobial agents explores a vast and interesting subject 
area. Therefore, a series of new carbamate derivatives of sulfathiazole 6a-e, a common oral antimicrobial drug and methyl 
tryptophanate 8a-e, N-methyl α-amino acid ester containing indole moiety have been synthesized. Structures of the  
title products have been elucidated by spectral analyses like IR, NMR (1H and 13C), mass and elemental composition.  
The compounds have been evaluated for their in vitro antimicrobial activity including minimum inhibitory concentrations 
(MICs). Whereas, three carbamate derivatives of sulfathiazole 6a, 6b and 6e and one derivative of methyl tryptophanate 8a 
show promising antibacterial activity in the range of MIC 2.88-8.14 µg/mL and it is a comparable activity of streptomycin 
(MIC = 3.14-7.43 µg/mL). Most of the compounds provide potent activity against E. coli which is equivalent to 
streptomycin (MIC = 3.14 µg/mL). The title compounds have been docked into the active site of E. coli DNA gyrase  
A enzyme to ensure the binding mode and the results demonstrate that a few compounds show better binding energies with 
enzyme than that of standard, streptomycin and associated with antibacterial activity. 
Keywords: Carbamate derivatives, sulfathiazole, methyl tryptophanate, antimicrobial activity, docking study, DNA gyrase A 
The infective diseases are among the most common 
complications in public health. The research discoveries 
attempted to give resolutions for infective diseases 
and the antibiotics are introduced in clinical use to 
control it1. Antibiotics utility has been enriched 
globally since it uses as modern medicine in invasive 
surgery and critical treatments like transplantation, 
cancer, and orthopedic related diseases. The 
consequence of abundant utility of antibiotics is 
bacterial resistance and it had a profound impact on 
the bacterial life on Earth’s system2,3. Problems 
related to currently used antibiotic drug-resistance 
against many human pathogens like Methicillin-
resistant Staphylococcus aureus (MRSA) and 
Vancomycin-resistant Enterococci (VRE) have been 
reported in the literature4,5. Therefore, it is of serious 
concern that the currently existing antibiotic drugs 
used in the treatment of infectious diseases are 
inadequate in the long term to protect us3. The World 
Economic Global Risks reports concluded that drug-
resistance is one of the greatest threats to human 
health. Hence, focused research is essential for the 
discovery of new antimicrobial agents which have a 
clear innovative mechanism of action and it should 
produce new compounds to overcome the microbial 
resistance to clinically used drugs. 
Peptide-based functionalities like carbamates and 
amides linkages, because of their high affinity and 
specificity toward biological functions, are attributed 
as an important strategy in drug discovery6-8. 
Particularly, carbamates display good chemical and 
proteolytic stabilities, and can participate in hydrogen 
bonding through the carboxyl group and the backbone 
NH. Also, they possess a unique ability to modulate 
inter- and intra-molecular interactions with the target 
enzymes or receptors. Hence, carbamates with 
substitution on numerous active scaffolds offer 
opportunities for modulation of biological properties, 
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improvement in stability and pharmacokinetic 
properties and capability to increase permeability 
across cellular membranes9. Because of these 
tremendous features, the carbamate group has become 
a key structural motif in drug design and discovery. 
Numerous carbamate-bearing molecules have been 
exploited rapidly in drug design, playing an important 
role in medicinal chemistry and found in many of the 
approved drugs and pro-drugs in the market9. For 
example, rivastigmine 1, albendazole 2 and felbamate 
3 (Figure 1) are used in the treatment of Alzheimer’s 
disease/Parkinson’s, parasitic worm infestations and 
epilepsy, respectively. In addition, the applications  
of carbamate derivatives are well reported in various 
industries, agrochemicals such as pesticides, fungicides, 
and herbicides, in the polymer industry, and in peptide 
syntheses10-12. Carbamate derivatives have also been 
reported in numerous biological applications such as 
inhibitors of HIV, anticancer agents, anticonvulsants, 
antibacterial agents, antiepileptic’s, and enzyme 
inhibitors13-19. Recently, our group synthesized carbamate 
derivatives of (2'-(1H-tetrazol-5-yl)- biphenyl-4-yl) 
methanamine, carvedilol, and 7-azaindole showed good 
antimicrobial and antiviral activities, respectively20-22. 
It is well established that sulfonamides possessing 
functionality, -SO2-NH- or sulfa drugs are accomplished 
a prominent role in the history of medicine as the first 
synthetic antibiotic medications to be used clinically23. 
Since then, thousands of compounds by substituting 
numerous chemical entities on sulfonamide group 
were synthesized and the best therapeutic outcomes 
have been accomplished, including antihypertensive 
agent bosentan24, antibacterial25, antiprotozoal26, 
antifungal27 and anti-inflammatory28 activities, and 
over 32 drugs are in clinical use29, Therefore, the 
sulfonamide compounds have been considered as key 
structural motifs in the search for biologically active 
molecules. Sulfathiazole, chemically N-2-thiazolyl 
sulfanilamide, is a short-acting sulfa drug used as 
antibiotic until less toxic alternatives were discovered. 
It has been using still in the treatment of infective 
diseases in combination with other non-sulfonamide 
drugs. A number of studies have been made on 
sulfathiazole to enhance its drug ability and 
properties, and suitability in other chemotherapeutic 
use. For example, various alkyl or aryl substituents  
on the thiazole nucleus of sulfathiazole30 against 
microbial strains and 4-{[(2-hydroxy-naphthalen-1-
yl)-phenyl-methyl]-amino}-N-thiazol-2-yl-
benzenesulfonamide against Staphylococcus aureus 
and Vibrio cholera with MIC = 4 × 10−3 mmol31 
showed potential activity. Furthermore, indole and its 
derivatives are an important class of heterocyclics, 
and found in wide variety of biological active 
scaffolds and naturally occurring compounds which 
exhibit numerous physiological properties32,33. The 
amino acid ester, methyl tryptophanate is a significant 
derivative of indole. Because vital role of tryptophan 
or its derivatives in protein biosynthesis, the 
production of important hormones like serotonin34, 
antimicrobial and immune regulatory functions of 
indoleamine 2,3-dioxygenase35,36 and as potential 
agents in various human-related diseases like cancer, 
neurodegenerative disorders, diabetes37,38-40. The 
chemistry of tryptophan derivatives has attained a 
great topic of research interest in medicinal chemistry. 
 
 
Figure 1 — Biologically active carbamate derivatives and title products 
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The structural modification of drugs or drug 
intermediates or biologically active compounds by 
assimilating with the class of pharmacophores have 
become more interest now a day to accomplish new 
drug lead compounds and potential chemotherapeutic 
agents41. It is also an important approach in the 
discovery of medicinal important molecules. In  
such a way, the derivatives of (2'-(1H-tetrazol-5-yl)- 
biphenyl-4-yl)methanamine20, carvedilol21, linezolid 
intermediate42 and acyclovir43 synthesized by our 
group by integrating carbamate functionality and 
phosphoramidites have exhibited potential antimicrobial 
and antiviral activities, respectively. As in the part of 
our continuous research, and considering the overview 
biological importance of sulfathiazole, methyl 
tryptophanate and carbamate derivatives, we here in 
report the synthesis, characterization and biological 
studies of new series of carbamates of sulfathiazole 
and methyl tryptophanate using conventional method. 
The title products were investigated for their 
antimicrobial activity including minimum inhibitory 
concentrations and a few compounds are acted as 
potential antimicrobial agents. Further, the ligand-
receptor interactions were understood by carrying out 
molecular docking studies. 
 
Results and Discussion 
 
Chemistry 
As a part of our continuous research efforts on the 
preparation of new biologically active compounds20-
22,45,50-52
 and considering the biological prominence  
of sulfathiazole 4, methyl tryptophanate 5, and 
carbamate derivatives as described above, we have 
been planned in the present study to understand the 
antimicrobial potency of carbamate derivatives of 
sulfathiazole and methyl tryptophanate. The general 
procedure used in our previous study20 with 
modifications was used to prepare carbamate derivatives 
of sulfathiazole 6a-e and methyl tryptophanate 8a-e 
and the schematic representation was depicted in 
Scheme I. Initially, sulfathiazole 4 was treated with  
4-nitrophenyl chloroformate 5a in THF solvent using 
DMAP as a base at ambient temperature for 10 h. The 
high amount of starting material 4 (based on TLC) 
was remained as an unreacted portion in the reaction 
mass, therefore the temperature was increased to 
reflux (60-65°C) and the reaction was completed 
within 7.0 h. Hence, we come to the conclusion  
that the electron-withdrawing group (-NH-SO2-) at 
para-position to amine group in compound 4 could 
impact on the reaction to progress in sluggish at 
ambient temperature. The reflux condition has been 
implemented to prepare the rest of all the sulfathiazole 
carbamate derivatives 6b-e. In contrast, the intensive 
impurities/ undesired products were observed (Based 
on TLC) while the reaction was carried out with 
methyl tryptophanate 7 under the same conditions. 
The side products could be formed by involving  
of indole amine or both desired aliphatic amine  
and undesired indole amine in the reaction at reflux 
condition. So, the same reaction was carried out at 
ambient temperature (30-45°C) and the high yield of 
desired product was observed, however, it took longer 
reaction time (5-10h). Therefore, this procedure has 
 
 
Scheme I — Synthesis of carbamates of sulfathiazole 6a-e and methyl tryptophanate 8a-e 
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been followed in the preparation of carbamate 
derivatives of methyl tryptophanate 8a-e. 
After completion of the reaction as judged by TLC, 
the salt, DMAP.HCl formed during the reaction was 
removed from the reaction mixture by filtration at 
45ºC. The filtrate was concentrated under vacuum to 
obtain crude product and it was subjected to column 
chromatography using different ratios of MeOH: 
DCM mixture as the mobile phase to obtain the pure 
products. The pure products were dried under vacuum 
at 45-50°C for 12 h and these products were used 
directly in further analysis. The structures, reaction 
time, yield and melting points range of the title 
products are tabulated in Table I. 
 
Spectroscopic analysis 
The structures of newly synthesized carbamate 
derivatives 6a-e and 8a-e, after purification, were 
elucidated using spectroscopic analysis like IR, NMR 
(1H and 13C), mass, and elemental analyses. In IR 
spectra of all the title compounds, the intense bands at 
3200-3400 cm−1 and 1680-1740 cm−1 were observed 
due to –NH and carbonyl (C=O) of carbamate 
functionality, however, two carbonyl groups are 
merged and showed one broad band in case of 
tryptophanate derivatives 8a-e. The CH proton of 
thiazole ring appeared as a singlet at δ 6.50-6.90 and 
the aromatic protons of phenyl ring showed peaks at δ 
7.05-7.75 in 1H NMR spectra of sulfathiazole carbamates 
6a-e. The indole protons showed chemical shifts in the 
range of δ 6.95-7.60 and aliphatic protons resonated at 
δ 4.75-325 in the carbamates of methyl tryptophanate 
8a-e. In 13C NMR spectra of all the title products, the 
carbonyl (−C=O) carbon appeared at δ 153-160 and 
the remaining carbons resonated at their corresponding 
positions. The molecular ion peaks in mass spectra 
displayed corresponding mass of products and the 
elemental (C H, N) compositions obtained in elemental 
analyses coincided with the theoretical compositions 
of the newly synthesized compounds, and provided 
further evidence in the structural elucidation. 
 
Biological activity 
The antibacterial and antifungal activities were 
screened for the newly synthesized carbamate 
derivatives of sulfathiazole 6a–e and methyl 
tryptophanate 8a–e to understand their biological 
potency. The available bacterial strains such as 
Staphylococcus aureus (ATCC 43300), Bacillus subtilis 
(ATCC 6633), Escherichia coli (ATCC 25922) and 
Klebsiella pneumoniae (ATCC 700603), and fungal 
strains like Fusarium oxysporium (MTCC-1755), 
Aspergillus niger (MTCC-1881) and Colletotrichum 
capsici (MTCC-2071) were used to demonstrate the 
antibacterial and antifungal activities, respectively. The 
antimicrobial activity of the tested compounds was 
assessed by measuring bacterial/fungal growth of zone 
of inhibition (ZOI) using agar well diffusion method44 in 
the screening of antibacterial activity and disc diffusion 
method45 in fungal activity investigation. The standard 
antibiotics such as streptomycin and fluconazole were 
used as positive controls in antibacterial and antifungal 
activities, respectively for the comparison of title 
products activity. The dimethyl sulfoxide (DMSO) used 
in the preparation of test samples was taken as a 
negative control and found to exhibit no activity against 
selected pathogens. The observed antibacterial activity 
results are tabulated in Table I and antifungal activity 
results in Table II. 
The antibacterial screening results disclosed that all 
the compounds have exhibited activity at both the 
concentrations, 50 and 100 µg/mL and most of them are 
closer to the standard drug, streptomycin. Whereas, the 
sulfathiazole carbamates such as compound 6a bearing 
4-nitrophenyl ring, 6b possessing methyl group and  
6e linked with a trichloroethyl group, and methyl 
tryptophanate carbamate, 8a bearing 4-nitrophenyl ring 
have shown potential activity against all the tested 
bacterial strains, and found that their activity was closer 
to the standard drug, streptomycin. Additionally, 
compounds 6c against B. subtilis (ATCC 6633), 6d 
against E. coli (ATCC 25922) and S. aureus (ATCC 
43300), 8c against K. pneumoniae (ATCC 700603), and 
8b, 8d and 8e against E. coli (ATCC 25922) exhibited 
excellent activity. While in comparison, more carbamate 
derivatives of sulfathiazole exhibited potential 
antibacterial activity as compared with carbamates of 
methyl tryptophanate and most of both compound 
derivatives are more effective agents against E. coli 
(ATCC 25922). Furthermore, substitution of the 
aromatic entity with the electron-withdrawing group  
(-NO2) showed better antibacterial activity than that of 
aliphatic chain substitution. However, the activity has 
become diminished upon increasing of aliphatic  
nature like methyl > ethyl > iso-propyl, and the activity  
has been enhancing while increased the electron-
withdrawing groups on the aliphatic chain (trichloro 
ethyl group 6e/8e). Therefore, the results released that 
electron-withdrawing groups play an important role to 
exhibit potential antibacterial activity, and could attain 
better results when substituted aromatic scaffolds 
possessing electron-withdrawing groups in drug design. 
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Table I — Structure, reaction time, yield and melting points of the title products 
Compd Structure Reaction time (h) Yield (%) m.p. (°C) 
6a 
 
6.0  89.5 128.1-129.1 
6b 
 
8.0 83.3 157.4-158.4 
6c 
 
8.5 82.0 184-185 
6d 
 
10.0 78.4 159.6-160.6 
6e 
 
8.0 85.0 173.4-174.4 
8a 
 
6.0 92.6 123.4-124.4 
8b 
 
14.0 88.0 85.4-86.4 
8c 
 
10.0 88.5 68.2-69.2 
8d 
 
12.0 85.3 83.8-84.8 
8e 
 
10.0 89.2 72.4-73.4 
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Table II — Minimum inhibitory concentrations of the newly synthesized carbamate derivatives 6a-e and 8a-e 
Compd 
Minimum inhibitory concentrations in µg/mL 
Kp E. coli S. aureus B. subtilis F. oxysporium A. niger C. capsici  
6a 4.164 2.888 4.138 5.166 4.186 3.106 3.812 
6b 5.424 6.322 6.844 5.112 5.288 6.144 6.812 
6c 8.416 8.222 8.464 7.136 6.928 8.144 7.388 
6d 7.312 6.864 8.112 8.146 7.113 8.124 7.914 
6e 4.986 3.122 5.608 4.814 4.008 3.014 3.946 
8a 5.116 4.814 6.628 4.484 5.006 3.912 4.188 
8b 3.212 4.082 6.624 4.814 3.814 4.012 4.116 
8c 6.118 7.308 8.200 8.460 7.618 8.422 8.618 
8d 8.114 8.426 6.366 7.132 7.882 8.142 7.818 
8e 4.158 3.436 7.118 5.212 4.328 4.118 2.928 
Std.a 4.328 3.146 7.432 5.012 4.116 3.864 4.318 
Std.b 5.164 5.882 4.118 4.016 3.814 6.116 5.988 
Std.a – The standard antibiotic, streptomycin was used as positive control in antibacterial activity; Std.b– The standard antibiotic, 
fluconazole was used as positive control in antifungal activity; Kp - Klebsiella pneumoniae (ATCC 700603); E. coli - Escherichia coli
(ATCC 25922); S. aureus - Staphylococcus aureus (ATCC 43300); B. subtilis - Bacillus subtilis (ATCC 6633); F. oxysporium –
Fusarium oxysporium (MTCC-1755); A. niger – Aspergillus niger (MTCC-1881); C. capsici – Colletotrichum capsici (MTCC-2071). 
 
As seen in Table II, all the compounds exhibited 
antifungal activity against all the tested fungal strains 
at both the concentrations 50 and 100 µg/mL, similar 
to antibacterial activity. In contrast to bacterial 
activity, very few compounds such as sulfathiazole 
carbamates 6a bearings 4-nitrophenyl ring and 6c 
bound with ethyl group, and one methyl tryptophanate 
derivative 8a bearing 4-nitrophenyl ring showed 
excellent activity against all the tested fungal strains. 
Whereas, most of the compounds showed promising 
activity against fungal strains discretely like 
compounds 6d and 8b against F. oxysporium (MTCC-
1755), 6e against C. capsici (MTCC-2017), 8d against 
A. niger (MTCC-1881), 8c against F. oxysporium 
(MTCC-1755) and C. capsici (MTCC-2017), and 8e 
against A. niger (MTCC-1881) and C. capsici 
(MTCC-2017). Based on the results, the compounds 
are more active against F. oxysporium (MTCC-1755) 
and C. capsici (MTCC-2017) than that of A. niger 
(MTCC-1881), and impotent to predict structure-
activity relationship. In whole observations, the title 
products are more effective against bacterial strains 
and also good to moderate activity against fungal 
strains. 
Because the excellent bacterial/fungal growth of 
zone of inhibition (ZOI) exhibited by the title 
carbamate derivatives 6a-e and 8a-e, our interest has 
been focused further to screen the minimum 
inhibitory concentrations (MIC) of the active 
compounds using the two-fold serial dilution 
technique46. The lowest concentration of target or  
test sample showing no growth of inhibition of 
microorganism is considered to be the minimum 
inhibitory concentration (MIC) and obtained results 
were tabulated in Table II. The compounds 6a, 6b, 
6d, 6e, and 8a showed excellent MIC values in the 
range, 2.88-8.14 µg/mL which are almost equal to the 
standard drug, streptomycin (3.14-7.43 µg/mL). In 
overall comparison, most of the compounds showed 
excellent activity against E. coli (ATCC 25922) and 
F. oxysporium (MTCC-1755) equal to the standard 
drugs, and the compounds 6a and 8a bound with the 
4-nitophenyl ring are more potent in both activities. 
 
Docking study 
Type IIA bacterial topoisomerases, DNA gyrase 
(gyrase) is an essential bacterial enzyme that catalyses 
the ATP-dependent negative super-coiling of double-
stranded closed-circular DNA and clinically validated 
pharmacological target for antibacterial drugs. The 
function of DNA gyrase is to catalyse the transient 
break and reunion of the DNA double strand, a 
process crucial for negative supercoiling or relaxation 
of positive supercoils in the DNA molecule during its 
replication. In addition, much attention has been 
focused on DNA gyrase as the intracellular target of a 
number of antibacterial agents, including nalidixic 
acid, novobiocin, ciprofloxacin and streptomycin and 
as a paradigm for other DNA topoisomerases. 
Furthermore, the standard antibiotic, streptomycin  
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is an aminoglycoside antibiotic derived from 
streptomycin griseous with antibacterial activity. 
Streptomycin irreversibly binds to the 16S rRNA and 
S12 protein within the bacterial 30S ribosomal subunit. 
As a result, this agent interferes with the assembly of 
initiation complex between mRNA and the bacterial 
ribosome, thereby inhibiting the initiation of protein 
synthesis. As well as, streptomycin induces misreading 
of the mRNA template and causes the translational 
frame shift, thereby results in premature termination. 
This eventually leads to bacterial cell death. 
Computational biology and bioinformatics play a 
vital role in the process of drug discovery and drug 
designing. The imperative information about drug-
receptor interactions can accomplish while docked the 
drug molecule with the receptor (target) which is 
commonly used to identify the binding orientation of 
drug candidates to their protein targets in order to 
predict the affinity and activity. The title carbamate 
derivatives of sulfathiazole 6a-e and methyl tryptophanate 
8a-e synthesized in the present study have been 
exhibited excellent to moderate antimicrobial activity, 
particularly antibacterial activity on E. coli. Therefore, 
the molecular docking studies were performed on 
DNA gyrase A enzyme from E. coli (PDB: 3LPX) to 
understand the mechanism of antibacterial activity of 
the newly synthesized carbamate derivatives. 
Automated docking studies were carried out using 
the docking module implemented in Pyrx 2010.12 to 
envisage the antimicrobial data on the structural 
basis47. The RCSB Protein Data Bank (PDB) and Pub 
Chem Data Bank were used to retrieve the three-
dimensional structure of DNA gyrase A from E. coli 
(PDB: 3LPX) (Figure 2a) and standard drugs such  
 
 
Figure 2 — Three dimensional structure of DNA Gyrase A, streptomycin and docking conformers of active newly synthesized compounds 
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as streptomycin (Pub Chem ID 19649) (Figure 2b), 
respectively. Argus Lab 4.0.was used for alienated 
and geometry optimization of the atomic coordinates 
of the protein and the chemical structures of target 
compounds were drawn in ChemBioDraw. The active 
binding sites nothing but the coordinates of the ligand 
in original target protein grids were analyzed using 
the Drug Discovery Studio version 3.0 and 3D Ligand 
Site Virtual tools. Flexible docking was employed  
and the inhibitor binding site residues were softened 
and highlighted through the “Site Finder” module 
implemented in the Pymol software. Pymol viewer 
tool (www.pymol.org),48, 49 after docking process, 
used to calculate the binding energy, residual binding 
interactions, bond length and their bond angles of the 
protein-ligand complexes were tabulated in Table III 
and the docked view or conformers of the active 
compounds have depicted in Figure 2c-f. 
As seen in Table III related to the docking results 
of the newly synthesized carbamate derivatives  
6a-e and 8a-e with DNA gyrase A displayed that 
carbamate derivatives, 6a (-7.7 Kcal/mol), 6e (-7.6 
Kcal/mol), 8b (-6.9 Kcal/mol) and 8e (-6.9 Kcal/mol) 
showed excellent binding affinity with the enzyme, 
DNA gyrase A, which is more than equal to the 
standard antibiotic, streptomycin (-6.9 Kcal/mol). 
Furthermore, the same compounds were well associated 
with in vitro antibacterial activity, particularly against 
E. coli. Furthermore, the compounds 6b, 6c, 6d and 
8a showed moderate binding energy in the range of -
6.5 to -6.7 Kcal/mol. 
Sulfathiazole carbamate 6a (Figure 2c), forms three 
hydrogen bonding interactions with amino acid 
residues at the active site of the enzyme, DNA gyrase 
A. The oxygen atoms of sulfoxide (SO2) forms one 
hydrogen bonding interaction with hydrogen of Asn 
Table III — Bonding characterization of the title products 6a-e and 8a-eagainst E. coli DNA Gyrase A protein 
Compd Rank Binding energy 
(Kcal/mol) 
Residue involved in  
binding interaction 
Bond length (Å) Bond 
`angle (°) 
Bond type 
6a 1 −7.7 
Gly 267 CG…ON 
Asn 269 ND…OS 
Arg 91 CZ….ON 
2.6 
2.3 
2.2 
114.9 
120.3 
121.8 
H-acc. 
H-acc. 
H-acc. 
6b 6 −6.6 
Asp 297 CA …..HN 
Lys 270 NZ …..OC 
Thr 219 CB ….HN 
2.0 
2.1 
2.6 
122.4 
110.3 
84.1 
H-don. 
H-acc. 
H-don. 
6c 8 −6.5 Asp 297 CA …..HN 2.1 122.4 H-don. 
6d 7 −6.6 
Phe 109 CA ….OS 
Asn 108 CG …..OS 
Leu 264 CA ….ON 
2.2 
2.1 
2.0 
115.1 
121.5 
114.7 
H-acc. 
H-acc. 
H-acc. 
6e 2 −7.6 
Asp 297 CA ….HN 
Thr 219 CG …..HN 
Lys 270 NZ ….OC 
2.0 
2.7 
2.2 
122.4 
110.9 
101.0 
H-don. 
H-don. 
H-acc. 
8a 5 −6.7 Asp 297 CA …..HN Aeg 518 CZ …..OC 
2.2 
2.8 
122.4 
122.4 
H-don. 
H-acc. 
8b 4 −6.9 Asn 169 CB ….HN Arg 91 CZ ….OC 
2.2 
2.4 
120.7 
118.6 
H-don. 
H-acc. 
8c 9 −6.4 Asn169 CB ….HN Gly 170 CA ….HN 
2.3 
2.0 
101.0 
122.3 
H-don. 
H-don. 
8d 10 −6.3 Asp 297 CA …..HN Leu 264 CA …..OC 
2.4 
2.1 
122.4 
114.7 
H-don. 
H-acc. 
8e 3 −6.9 
Asn 169 CA …..HN 
Gly 170 CA …..HN 
Arg 91 CZ …..OC 
2.4 
2.7 
2.4 
120.7 
122.3 
121.8 
H-don. 
H-don. 
H-acc. 
Std. R −6.9 
Arg 139 CG…HN 
Leu 135 CD…HN 
His 132 CB…OH 
Asp 53 CG…OC 
Asp 53 OC…OC 
Asp 58 OD…OH 
Asp 58 OD…HN 
His 132 ND…OC 
His 132 ND…OC 
His 132 OC…OH 
2.2 
2.7 
2.5 
3.4 
2.9 
2.0 
2.5 
2.8 
2.7 
2.5 
124.4 
125.7 
125.0 
116.7 
118.9 
118.6 
116.4 
126.2 
120.0 
119.8 
H-don. 
H-don. 
H-acc. 
H-acc. 
H-acc. 
H-acc. 
H-don. 
H-acc. 
H-acc. 
H-acc. 
Std. – Streptomycin was used as reference standard; H-acc indicates hydrogen accepter; H-don indicates hydrogen donar. 
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269, nitrogen atom of nitro group and amide 
carbamate forms one hydrogen bonding interaction 
with Gly 267 and Arg 91, respectively. Compound 6e 
(Figure 2d) forms three hydrogen bonding interaction, 
whereas nitrogen atom from thiazole ring and 
carbamate forms hydrogen bonding interactions with 
Thr 219 and Asp 297, respectively, and one hydrogen 
bonding interaction of oxygen in carbonyl with Lys 
270. In the similar fashion, the methyl tryptophanate 
derivatives 8b and 8c form each two hydrogen 
bonding interactions. The nitrogen atom in indole 
moiety with Asn 169 both in compounds 8b and 8c, 
oxygen atom of carbonyl group in compound 8b with 
Arg 91 (Figure 2e), and nitrogen of carbamate in 
compound 8c Gly 170 (Figure 2f) form hydrogen 
bonding interactions. The binding modes of compounds 
6a, 6e, 8b and 8e, suggesting that they fitted more 
stably into the DNA gyrase binding pocket. Hence, 
the present investigation demonstrates that the 
synthesized compounds will be the promising next 
generation antimicrobial drugs, and can be effectively 
used in the treatment of microbial and other related 
infections. 
 
Experimental Section 
The key starting materials like sulfathiazole, 
methyl tryptophanate and substituted chloroformates 
used in the synthesis of title products were procured 
from Sigma-Aldrich with purity >99% and used as 
received without any further purification. The analytical 
grade solvent, tetrahydrofuran (THF) was used in the 
reactions as medium and it was purchased from 
Spectrochem, and other solvents like dichloromethane 
(DCM), methanol (MeOH) and ethyl acetate (EtOAc) 
used in the work-up procedure and purification 
techniques were purchased commercially. The progress 
of the reactions and homogeneity of compounds were 
examined on Merck silica plates and the suitable ratio 
of DCM: MeOH (mostly in the range between 9.2:0.8 
v/v to 9.8:0.2 v/v) was used as a mobile phase.  
The temperature was measured by flexible probe 
throughout the reaction. The silica gel (200 mesh) 
procured from Spectrochem was used in column 
chromatography for purification of the synthesized 
compounds. Melting points were determined in open 
capillaries on Guna Digital Melting point apparatus 
and are uncorrected, and they are expressed in  
degrees centigrade (°C). The IR spectra were recorded 
directly on Bruker Alpha FT-IR spectrophotometer 
without using KBr pellets and the wave numbers  
are given in cm−1. The 1H and 13C NMR spectra  
were recorded in CDCl3 on a Bruker 400 MHz 
spectrophotometer operating at 400 MHz for 1H NMR 
and 100 MHz for 13C NMR. All chemical shifts were 
reported in δ (ppm) using TMS as an internal standard 
and multiplicities are described as the abbreviations: s 
(singlet), brs (broad singlet), d (doublet), t (triplet), m 
(multiplet). The elemental analyses were determined 
on Thermo Finnegan Flash 1112 elemental analyzer. 
E.S.I mass spectra were recorded on a MLP 2103 
mass spectrometer. 
 
General procedure for the synthesis of title products 
 
Synthesis of carbamates of sulfathiazole 
To the solution of sulfathiazole 4 (150 mg, 0.59 
mmol) and 4-N,N-dimethylamino pyridine (DMAP) 
(86.7 mg, 0.71 mmol) in THF (10 mL) was added  
4-nitrophenyl chloroformate 5a (131.0 mg, 0.65 
mmol) dissolved in 3 mL of THF at 10-15°C. The 
reaction mixture was heated to 60-65°C and it was 
stirred for 5 h. The progress of a reaction was 
monitored by TLC using DCM: MeOH (9.2:0.8 v/v) 
mixture as a mobile phase and it confirmed the 
reaction completion. The reaction mixture was 
filtered-off to remove the salt DMAP.HCl (discarded 
the salt) and cooled the reaction mass to 20-25°C. The 
solvent from the filtrate was removed under vacuum, 
to obtain the crude residue and it was subjected to 
column chromatography using DCM: MeOH mixture 
as a mobile phase. The desired fractions of target 
product were confirmed together and the solvent was 
removed under vacuum to obtain 4-nitrophenyl 4-(N-
thiazol-2-ylsulfamoyl) phenyl carbamate 6a as pale 
yellow solid. The same procedure was followed for 
the preparation of the remaining carbamate analogs of 
sulfathiazole 6b-e. 
 
Synthesis of carbamates of methyl tryptophanate 
4-Nitrophenyl chloroformate 5a (153 mg, 0.76 m 
mol) in THF (5mL) was added to the solution of 
methyl tyrptophanate 7 (150 mg, 0.69 mmol) and  
4-N,N-dimethylamino pyridine (DMAP) (109.6 mg, 
0.90 mmol) in THF (10 mL) at 10-15°C. The reaction 
mixture was stirred for 10 h at ambient temperature 
(25-30°C). The completion of the reaction was judged 
based on TLC using DCM: MeOH mixture (9.5:0.5 
v/v) as a mobile phase. The reaction mixture was 
filtered-off to remove the salt DMAP.HCl (the salt 
was discarded) and the solvent from the filtrate was 
removed under vacuum to obtain the crude residue 
which was subjected to column chromatography using 
DCM: MeOH mixture system as a mobile phase. The 
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combined desired product fractions were evaporated 
under vacuum to obtain methyl 3-(1H-indol-3-yl)-2-
((4-nitrophenoxy) carbonylamino) propanoate 8a as a 
pale yellow solid. The same procedure was adopted 
for the preparation of the remaining carbamate 
analogs of tryptophanate 8b-e. 
 
Spectral data 
4-Nitrophenyl 4-(N-thiazol-2-ylsulfamoyl)phenyl- 
carbamate, 6a: Pale yellow solid. Yield 89.5%. m.p. 
128.1-129.1°C. IR: 3383, 3223 (N-H, str), 2962 (C-H, 
str), 1741 (C=O, str), 1518 & 1265 (-NO2, str), 1339 
cm−1 (SO2, str); 1H NMR (400 MHz, CDCl3): δ 7.70 
(2H, d, J = 7.6 Hz, Ar-H), 7.45-7.60 (4H, m, Ar-H), 
7.05-7.11 (3H, m, Ar-H &thiazole-H), 6.57 (1H, d, J 
= 9.2 Hz, S-CH in thiazole); 13C NMR (100 MHz, 
CDCl3): δ 108.1, 119.3, 123.6, 125.9, 128.5, 133.7, 
137.0, 142.6, 145.2, 152.9, 159.2, 170.4; ESI-MS: 
m/z 421.1 (M+H+). Anal. Calcd for: C, 45.71; H, 
2.88; N, 13.33. Found: C, 45.68; H, 2.87; N, 13.32%. 
Methyl 4-(N-thiazol-2-ylsulfamoyl)phenyl-carbamate, 
6b: Pale yellow solid. Yield 83.3%. m.p. 208-212 °C. 
IR: 3301, 3185 (N-H, str), 2953 (C-H, str), 1719 
(C=O, str), 1317 cm−1 (SO2, str); 1H NMR (400 MHz, 
CDCl3): δ 7.73 (2H, d, J = 8.0 Hz, Ar-H), 7.49 (2H, d, 
J = 8.0 Hz, Ar-H), 7.18 (1H, d, J = 9.2 Hz, thiazole-
H), 6.55 (1H, d, J = 9.2 Hz, S-CH in thiazole), 3.84 
(3H, s, -O-CH3); 13C NMR (100 MHz, CDCl3): δ 
58.4, 110.2, 118.8, 128.4, 134.0, 137.6, 142.9, 154.3, 
169.7; ESI-MS: m/z 314.05 (M+H+). Anal. Calcd for: 
C, 42.16; H, 3.54; N, 13.41. Found: C, 42.13; H, 3.51; 
N, 13.40%. 
Ethyl 4-(N-thiazol-2-ylsulfamoyl) phenylcarbamate, 6c: 
Pale yellow solid. Yield 82.0%. m.p. 208-212 °C. IR: 
3299, 3101 (N-H, str), 2976 (C-H, str), 1704 (C=O, 
str), 1277 cm−1 (SO2, str); 1H NMR (400 MHz, 
CDCl3): δ 7.71 (2H, d, J = 8.0 Hz, Ar-H), 7.44 (2H, d, 
J = 8.0 Hz, Ar-H), 7.15 (1H, d, J = 8.8 Hz, thiazole-
H), 6.62 (1H, d, J = 9.2 Hz, S-CH in thiazole), 4.02 
(2H, q, J = 8.4 Hz, -O-CH2-), 1.16 (3H, t, J = 8.4 Hz, 
-C-CH3); 13C NMR (100 MHz, CDCl3): δ 14.1, 62.5, 
107.1, 117.7, 123.5, 127.1, 133.2, 138.0, 142.6, 153.3, 
169.1; ESI-MS: m/z 328.05 (M+H+). 
Isobutyl 4-(N-thiazol-2-ylsulfamoyl)phenylcarbamate, 
6d: Pale yellow solid. Yield 78.4%;m.p. 208-212 °C. 
IR: 3352, 3109 (N-H, str), 2954 (C-H, str), 1728 
(C=O, str), 1295 cm−1 (SO2, str); 1H NMR (400 MHz, 
CDCl3): δ 7.65 (2H, d, J = 8.0 Hz, Ar-H), 7.42 (2H, d, 
J = 8.0 Hz, Ar-H), 7.15 (1H, d, J = 9.2 Hz, thiazole-
H), 6.58 (1H, d, J = 9.2 Hz, S-CH in thiazole), 3.97 
(2H, d, J = 8.0 Hz, -O-CH2-), 1.82 (1H, m, -C-CH-), 
0.96 (6H, d, 8.0 Hz, -C-(CH3)2); 13C NMR (100 MHz, 
CDCl3): δ 18.3, 30.1, 68.4, 109.3, 118.0, 123.9, 129.5, 
134.1, 137.3, 141.8, 153.1, 170.8; ESI-MS: m/z 
356.06 (M+H+). 
2,2,2-Trichloroethyl 4-(N-thiazol-2-ylsulfamoyl) 
phenylcarbamate, 6e: Pale yellow solid. Yield 
85.0%. m.p. 208-212 °C. IR: 3304, 3152 (N-H, str), 
2945 (C-H, str), 1720 (C=O, str), 1316 (SO2, str), 
1172 cm−1 (CCl3, str); 1H NMR (400 MHz, CDCl3): δ 
7.73 (2H, d, J = 8.4 Hz, Ar-H), 7.43 (2H, d, J = 8.4 
Hz, Ar-H), 7.18 (1H, d, J = 8.8 Hz, thiazole-H), 6.57 
(1H, d, J = 8.8 Hz, S-CH in thiazole), 4.89 (2H, s, -O-
CH2-CCl3); 13C NMR (100 MHz, CDCl3): δ 73.9, 
95.3, 110.2, 116.5, 125.0, 128.7, 132.4, 137.1, 142.0, 
153.8, 170.2; ESI-MS: m/z 430.0 (M+H+). 
Methyl 3-(1H-indol-3-yl)-2-((4-nitrophenoxy) 
carbonylamino)propanoate, 8a: Pale yellow solid. 
Yield 92.6%. m.p. 123.4-124.4°C. IR: 3410, 3326 (N-
H, str), 2942 (C-H, str), 1723 (broad, C=O, str), 1519 
& 1278 cm−1 (-NO2, str); 1H NMR (400 MHz, 
CDCl3): δ 8.19 (2H, d, J = 8.4 Hz, Ar-H), 7.57 (1H, d, 
J = 7.6 Hz, Ar-H), 7.34 (2H, d, J = 8.4 Hz, Ar-H), 
7.14-7.25 (3H, m, Ar-H), 7.04 (1H, s, indole-H), 4.75 
(1H, m, -CH-), 3.65 (3H, s, -O-CH3), 3.31 (2H, m, -
CH2); 13C NMR (100 MHz, CDCl3): δ 29.3, 48.9, 
52.3, 111.4, 113.2, 117.2, 118.5, 120.8, 122.3, 123.4, 
124.9, 127.5, 140.9, 142.3, 154.2, 155.7, 170.1; ESI-
MS: m/z 384.1 (M+H+). Anal. Calcd for: C, 59.53; H, 
4.47; N, 10.96. Found: C, 59.51; H, 4.46; N, 10.96%. 
Methyl 3-(1H-indol-3-yl)-2-(methoxycarbonylamino) 
propanoate, 8b: Pale yellow solid. Yield 88.0%. m.p. 
208-212 °C. IR: 3321 (broad, N-H, str), 3009 (C-H, 
str), 1700 cm−1 (broad, C=O, str); 1H NMR (400 
MHz, CDCl3): δ 7.42 (1H, d, J = 8.0 Hz, Ar-H), 7.27 
(1H, d, J = 8.0 Hz, Ar-H), 6.95-7.18 (3H, m, Ar-H, 
indole-H), 4.47 (1H, m, -CH-), 3.56 (3H, s, -O-CH3), 
3.29(3H, s, -OCH3), 3.20 (2H, m, -CH2); 13C NMR 
(100 MHz, CDCl3): δ 29.0, 48.5, 52.3, 52.6, 110.1, 
113.4, 117.0, 118.4, 121.3, 123.6, 126.5, 141.2, 156.3, 
169.; ESI-MS: m/z 277.09 (M+H+). 
Methyl 2-(ethoxycarbonylamino)-3-(1H-indol-3-
yl)propanoate, 8c: Pale yellow solid. Yield 88.5%. m.p. 
208-212 °C. IR: 3338 (broad, N-H, str), 2988 (C-H, str), 
1699 cm−1 (broad, C=O, str); 1H NMR (400 MHz, 
CDCl3): δ 7.65 (1H, d, J = 8.0 Hz, Ar-H), 7.38 (1H, d,  
J = 8.0 Hz, Ar-H), 7.13 (1H, s, indole-H), 7.05-7.13 (2H, 
m, Ar-H), 4.48 (1H, m, -CH-), 4.05 (2H, q, J = 6.8 Hz, -
OCH2), 3.65 (3H, s, -O-CH3), 3.10-3.16 (2H, m, -
CH2),1.19 (3H, t, J = 6.8 Hz, -CH3); 13C NMR (100 
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MHz, CDCl3): δ 13.5, 28.7, 49.4, 51.8, 58.3, 110.5, 
112.9, 118.4, 118.9, 120.5, 122.9, 127.0, 139.7, 157.5, 
170.3; ESI-MS: m/z 291.1 (M+H+). 
Methyl 3-(1H-indol-3-yl)-2-(isobutoxycarbonyl-
amino)propanoate, 8d: Pale yellow solid. Yield 
85.3%. m.p. 208-212°C. IR: 3384, 3314 (N-H, str), 
2995 (C-H, str), 1738, 1689 cm−1 (broad, C=O, str); 
1H NMR (400 MHz, CDCl3): δ 7.52 (1H, d, J = 8.0 
Hz, Ar-H), 7.34 (1H, d, J = 8.0 Hz, Ar-H), 7.18  
(1H, s, indole-H), 7.1-6.983 (2H, m, Ar-H), 5.23  
(1H, m, -CH-), 3.83 (2H, d, J = 6.4 Hz, -OCH2), 3.66 
(3H, s, -O-CH3), 3.29 (2H, m, -CH2),1.88 (1H, m, -
CH). 0.88 (6H, d, J = 6.8 Hz, -(CH3)2); 13C NMR  
(400 MHz, CDCl3): δ 19.2, 28.04, 28.1, 52.3, 54.5, 
70.1, 110.1, 111.2, 118.7, 119.7, 122.3, 122.8, 127.6, 
136.2, 156.2, 172.6; ESI-MS: m/z 319.4 (M+H+). 
Methyl 3-(1H-indol-3-yl)-2-((2,2,2-trichloroethoxy) 
carbonylamino)propanoate, 8e: Pale yellow solid. 
Yield 89.2%. m.p. 208-212 °C. IR: 3380, 3296 (N-H, 
str), 2991 (C-H, str), 1725, 1694 (broad, C=O, str), 
1156 cm−1 (-CCl3, str); 1H NMR (400 MHz, CDCl3): δ 
7.47 (1H, d, J = 8.0 Hz, Ar-H), 7.35 (1H, d, J = 8.0 
Hz, Ar-H), 7.15 (1H, s, indole-H), 7.06 (2H, m,  
Ar-H), 4.72 (2H, s, -OCH2), 4.64 (1H, m, -CH-), 3.69 
(3H, s, -O-CH3), 3.26 (2H, m, -CH2); 13C NMR (100 
MHz, CDCl3): δ 28.8, 49.3, 50.9, 68.7, 98.2, 110.2, 
113.5, 117.6, 119.0, 120.3, 122.4, 126.1, 139.2, 156.5, 
170.5; ESI-MS: m/z 393.1 (M+H+). 
 
Biological activity 
 
Antibacterial activity 
Antibacterial activity of the newly synthesized 
carbamate derivatives of sulfathiazole 6a-e and 
tryptophanate 8a-e was demonstrated using agar well 
diffusion method as reported by Murray et al.44 with 
minor modifications. Streptomycin is an antibiotic as 
well effective DNA gyrase inhibitor often used to 
treat numerous bacterial infections; therefore it was 
used as a standard drug in this study for comparison 
of activity results. Stock solutions of the title products 
6a-e and 8a-e, and standard drug, streptomycin 
(positive control) were prepared in dimethyl sulfoxide 
(DMSO) solvent which was used as a negative 
control, and then the samples were diluted to required 
concentrations, 50 and 100 µg/mL. The bacterial 
strains, American Type Culture Collection (ATCC), 
such as Klebsiella pneumoniae (ATCC 700603), 
Escherichia coli (ATCC 25922), Staphylococcus 
aureus (ATCC 43300) and Bacillus subtilis (ATCC 
6633) were collected from Sri Venkateswara 
University, Department of Microbiology, Tirupati to 
investigate the antibacterial activity. These strains 
were sub-cultured previously in appropriate media 
under gaseous conditions to confirm their purity at 
35°C for 48 h prior to testing of the vehicles.  
The inoculums of different bacteria were spread over 
the nutrient agar medium (peptone, beef extract, 
NaCl, and agar-agar) and wells of bore size (6 mm) 
were made in the solid medium, after cooling, using a 
sterile metallic borer. The test samples of synthesized 
compounds in different concentrations, positive 
control, and negative control were poured into each 
cavity of different plates. The culture plates were  
kept at room temperature for 1 h to diffuse the drug  
in surrounding medium and then incubated at 37°C 
for 24 h. The diameter of the zone of inhibition formed 
around the cavities after incubation was accurately 
measured in mm. The duplicate experiments were 
performed and taken the average values as the final 
results and they are tabulated in Table SI. 
 
Antifungal activity 
The antifungal activity was demonstrated by 
following disc diffusion method as we described in 
the earlier study45 with modifications. The available 
fungal strains such as Fusariumoxysporum (MTCC-
1755), Aspergillus niger (MTCC-1881) and 
Colletotrichum capsici (MTCC-2071) were taken to 
investigate the bio-potency of title products. The 
standard drug fluconazole was used as positive 
control for comparison of antifungal activity results. 
The culture for about 48 h old of selected fungi was 
mixed with sterile physiological saline and the 
turbidity was adjusted to the standard inoculum of 
Mc-Farland scale 0.5 ≈106 colony forming unit (CFU) 
per mL. This culture with the help of a sterile glass 
spreader was spread on a surface of the solidified 
potato dextrose agar (Hi-media) media to attain  
even distribution of the inoculum. Sterile discs of 
Whatmann No.1 filter paper of about 8 mm diameter 
infused in the test samples of different concentrations 
such as 50 and 100µg/mL, and positive and negative 
controls are placed on the culture plates. The 
inoculated Petri plates were incubated for 72 h at 
25°C. The zone of inhibition of fungi around the disc 
was measured in millimeters as an edge to edge zone 
of the confluent growth which corresponds to the 
sharpest edge of the zone. The tests were repeated in 
duplicate and taken the average values as the final 
readings and they are given in Table SII. 
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Minimum inhibitory concentrations 
The lowest concentration of test sample showing 
no growth of inhibition of microorganism is 
considered to be the minimum inhibitory concentration 
(MIC). The two-fold serial dilution technique46 was 
used to investigate the minimum inhibitory concentrations 
(MICs) of the active title compounds which were 
categorized based upon the potential zone of growth 
of inhibition screened at two different concentrations 
like 50 and 100 µg/mL. The microorganism suspensions 
(106 CFU/mL), which have been used in the 
investigation of antibacterial and antifungal activities, 
were used to inoculate the test compounds in their 
suitable broth. The test samples of selected active 
compounds and the standard reference drugs were 
prepared in proper nutrient broth and their 
concentrations were adjusted to the concentration 
range of 50.0, 25.0, 12.5, 6.25 and 3.125 mg/mL.  
The culture plates of bacteria and fungi were incubated 
at 37°C for 24 and 48 h, respectively. Finally, the  
growth of microorganisms was observed by turbidity 
measurements and the results are tabulated in Table II. 
 
Docking study 
A set of newly synthesized carbamate derivatives 
of sulfathiazole and tryptophanate and reference 
standard drugs, streptomycin were evaluated their 
binding interactions with DNA gyrase A enzyme 
(PDB: 3LPX) using the docking module implemented 
in Pyrx 2010.12. The RCSB Protein Data Bank (PDB) 
and Pub Chem Data Bank were used to retrieve the 
three-dimensional structure of DNA gyrase A (PDB: 
3LPX) and standard drugs such as streptomycin (Pub 
Chem ID 19649), respectively. Argus Lab 4.0 was 
used for alienated and geometry optimization of the 
atomic coordinates of the protein. The chemical 
structures of desired the title carbamate derivatives 
were drawn in Chem. Bio Draw and all these 
structures were converted to energy minimized 3D 
structures in the pdbqt file format, and the atomic 
coordinates were generated using Pyrx 2010.12. The 
active binding sites nothing but the coordinates of the 
ligand in the original target protein grids were 
analyzed using the Drug Discovery Studio version  
3.0 and 3D Ligand Site Virtual tools. In order to get 
the stable conformers, the protein structures were 
protonated initially with the addition of polar 
hydrogen’s and then done energy minimization with 
the MMFF94x force field. Flexible docking was 
employed and the inhibitor binding site residues were 
softened and highlighted through the “Site Finder” 
module implemented in the Pymol software47-49  
The grid dimensions were predicted as ˚ X: 28.27,  
Y: 27.13, Z: 28.51. The default parameters i.e., 
placement: triangle matcher, recording 1: London  
dG and refinement: force field were carried out in  
the docking study, as well as a maximum of 10 
conformations of each compound, were allowed to be 
saved in a separate database file in a .mdb format. 
Pymol viewer tool (www.pymol.org), after docking 
process, used to calculate the binding energy and 
binding affinity of the protein-ligand complexes were 
tabulated in Table III. 
 
Conclusion 
The bacteria resistance is one of the utmost threats 
to human health and the research for the discovery of 
new antimicrobial agents with stringent mechanistic 
action explores recently a great interesting subject 
matter. In the present study, a series of new carbamate 
derivatives of sulfathiazole 6a-e and methyl tryptophanate 
8a-e was accomplished to understand their biological 
action and characterized well. The compounds were 
evaluated for their in vitro antimicrobial activity 
against four bacterial strains and three fungal strains 
including minimum inhibitory concentrations (MICs) 
for active compounds. Whereas, three carbamate 
derivatives of sulfathiazole 6a bonded with 4-
nitrophenyl ring, 6b bearing with methyl group and 6e 
bound with 2,2,2-trichloroethyl group and one 
derivative of methyl tryptophanate 8a bound with 4-
nitrophenyl ring showed promising antibacterial 
activity in the range MIC 2.88-8.14 µg/mL and it is 
comparable activity of standard drug, streptomycin 
(MIC = 3.14-7.43 µg/mL). Most of the compounds 
provided potent activity against E. coli and it was 
equivalent to standard (MIC = 3.14 µg/mL). A few of 
the compounds showed good to moderate activity 
against fungal strains. The title compounds were 
docked into the active site of E. coli DNA gyrase  
A enzyme to ensure the binding mode of newly 
synthesized carbamate derivatives. The molecular 
docking study results demonstrated that a few 
compounds (6a, 6e, 8b and 8c) showed better binding 
energies (≥ -6.9 Kcal/mol) with enzyme than that of 
standard antibiotic, streptomycin (-6.9 Kcal/mol)  
and the same compounds were associated well  
with in vitro antibacterial activity, particularly on  
E. coli inhibition. Therefore, the present investigation 
demonstrates that further suitable structural changes 
in the respect of substitution of new pharmacophore 
units on synthesized compounds could lead to the 
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promising next generation antimicrobial drugs, and 
can be effectively used in the treatment of microbial 
and other related infections. 
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